More on Array Biopharma (ARRY): Q2 beats as per share losses come in less-than-expected. CEO Ron...

|About: Array BioPharma Inc. (ARRY)|By:, SA News Editor

More on Array Biopharma (ARRY): Q2 beats as per share losses come in less-than-expected. CEO Ron Squarer notes strong progress across its pipeline, with Novartis saying it's set to begin Phase 3 trials of MEK162, and AstraZeneca set to start Phase 3 trials with selumetinib in non-small cell lung cancer during the second half of 2013.